Efficacy and safety of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer (NSCLC): a systematic literature review.

Oncoimmunology · 2020 · PMC7458604 · PMID 32923134

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Overall survival was longer with nivolumab plus chemotherapy than with chemotherapy alone, but the difference did not reach statistical significance (median 15.2 versus 12.2 months; HR 0.78; 97.72% CI: 0.60–1.02, see Figure 2(a )).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.